유전성 혈관부종 치료제 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Hereditary Angioedema Therapeutics Market size is expected to reach USD 9.18 Billion in 2034 from USD 4.73 Billion (2025) growing at a CAGR of 7.66% during 2026-2034.

The Global Hereditary Angioedema Therapeutics Market is experiencing consistent growth due to increasing awareness and improved diagnostic capabilities. Hereditary angioedema (HAE) is a rare genetic disorder requiring targeted treatment approaches, and advancements in biologics and plasma-derived therapies have significantly improved patient outcomes. Growing patient advocacy and better access to specialized care centers are also contributing to market expansion.

Market growth is driven by ongoing clinical research, regulatory approvals for novel therapies, and rising healthcare expenditure. Pharmaceutical companies are investing heavily in innovative treatments, including monoclonal antibodies and gene-based therapies. Additionally, favorable reimbursement policies in developed economies are enhancing patient access to advanced therapeutics.

Future prospects are optimistic as pipeline products and precision medicine approaches gain traction. The development of long-acting and self-administered therapies is expected to improve patient convenience and adherence. As awareness campaigns and genetic screening initiatives expand globally, the hereditary angioedema therapeutics market is likely to achieve sustained and progressive growth.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Treatment

• C1-Esterase Inhibitor
• Bradykinin B2 Receptor Antagonist
• Kallikrein Inhibitor
• Others

By End-use

• Prophylaxis
• On-Demand

By Route of Administration

• Intravenous
• Subcutaneous
• Oral

COMPANIES PROFILED

• BioCryst Pharmaceuticals Inc, Ionis Pharmaceuticals, CSL, Attune Pharmaceuticals, Adverum Biotechnologies Inc, KalVista Pharmaceuticals Inc, Takeda Pharmaceutical Company Limited, Pharming
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET: BY TREATMENT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Treatment
• 4.2. C1-Esterase Inhibitor Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Bradykinin B2 Receptor Antagonist Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Kallikrein Inhibitor Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET: BY END-USE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast End-use
• 5.2. Prophylaxis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. On-Demand Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Route Of Administration
• 6.2. Intravenous Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Subcutaneous Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Treatment
  • 7.2.2 By End-use
  • 7.2.3 By Route Of Administration
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Treatment
  • 7.3.2 By End-use
  • 7.3.3 By Route Of Administration
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Treatment
  • 7.4.2 By End-use
  • 7.4.3 By Route Of Administration
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Treatment
  • 7.5.2 By End-use
  • 7.5.3 By Route Of Administration
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Treatment
  • 7.6.2 By End-use
  • 7.6.3 By Route Of Administration
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 BioCryst Pharmaceuticals Inc
  • 9.2.2 Ionis Pharmaceuticals
  • 9.2.3 CSL
  • 9.2.4 Attune Pharmaceuticals
  • 9.2.5 Adverum Biotechnologies Inc
  • 9.2.6 KalVista Pharmaceuticals Inc
  • 9.2.7 Takeda Pharmaceutical Company Limited
  • 9.2.8 Pharming